Gain-of-function bcl-2 inhibitors
AssigneeFred Hutchinson Cancer Research Center
InventorsDavid HOCKENBERY, Julian SIMON
Life of this patent
Estimating the term…
Loading patent…
AssigneeFred Hutchinson Cancer Research Center
InventorsDavid HOCKENBERY, Julian SIMON
Estimating the term…
Compounds are described that are useful for treating an apoptosis-associated disease, which are specifically cytotoxic to tumor cells that are overexpressing Bcl-xL, and are much less cytotoxic in isogenic cells that are not overexpressing Bcl-xL. Also described is a method for treating an apoptosis-associated disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an active compound that is specifically cytotoxic to tumor cells that are overexpressing Bcl-xL, and are much less cytotoxic in isogenic cells that are not overexpressing Bcl-xL. Several scaffolds of active compounds are described.
An isolated compound consisting of Formula I
2-3. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
13-15. (canceled)
17-19. (canceled)
21-22. (canceled)
A compound consisting of the structure of Formulas II or III,
24-40. (canceled)
A method for treating an apoptosis-associated disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an active compound of Formula IV, V, or VI:
43-50. (canceled)
A method for treating an apoptosis-associated disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an active compound of Formula VII:
52-53. (canceled)
55-60. (canceled)
Dependencies are inferred from the claim text.